Bilateral stellate ganglion block for migraine
A case report
Su-Young Moon, MD<sup>a</sup>, Joonhee Lee, MD<sup>a</sup>, Younghoon Jeon, MD<sup>b</sup>,*

Abstract
Rationale: Migraine is a recurrent, disabling neurovascular headache disorder. The patient’s quality of life can be severely impaired by migraine attacks. Stellate ganglion block (SGB) can be used to relieve pain in the head, neck, and upper extremities. In the present cases, we performed SGB in 2 patients with migraine that responds poorly to drugs.

Patient concerns: Patients 1 and 2 suffered from chronic, bilateral pulsating headache, accompanied by nausea and vomiting. Patient 1 presented with headache of 8 on the visual analog scale (VAS), and 37 on the migraine disability assessment (MIDAS). Patient 2 reported headache of 7 on the VAS, and 32 on the MIDAS.

Diagnosis: The patients were diagnosed with migraine without aura based on the International Classification of Headache Disorders version 3.

Interventions: Patient 1 was treated with bilateral SGB every week for a month and then every month for 3 months. Patient 2 received bilateral SGB every 2 weeks and then every month for 3 months.

Outcomes: Four months after SGB, patient 1 reported pain intensity of 4 on VAS and 6 on MIDAS and patient 2 rated pain intensity of 3 on VAS, and 6 on MIDAS, respectively.

Lessons: The SGB can be an effective option to improve headache-related disability and relieve pain intensity in the patients with refractory migraine.

Abbreviations: MIDAS = migraine disability assessment, SGB = stellate ganglion block, VAS = visual analog scale.

Keywords: headache, migraine, pain, stellate ganglion block, sympathetic nerve.

1. Introduction
Migraine is a common, recurrent, disabling neurovascular headache disorder initiated by many trigger factors, such as stress, sleep deprivation, hunger, prolonged sensory stimulation, and hormonal variation.[1] Until now, the exact neurovascular pathogenesis of migraine remains unclear. It was reported that migraine headache depends on an altered excitability or dysfunction of the brain state by the activation of the trigeminovascular pathway.[2,3] Migraine is typically a pulsating and throbbing headache that can be unilateral or bilateral, accompanied by nausea, vomiting, muscle stiffness, and increased sensitivity to light, noise, smell, and touch. In addition, before a migraine attack, warning signs (premonitory symptoms) such as fatigue, mood change, food craving, and increased yawning and aura often occur; are derived from the hypothalamus, brainstem, and cortex.[2,3]

Patients’ quality of life can be severely impaired by migraine attacks. Migraine Disability Assessment (MIDAS) questionnaire was designed to measure headache-related disability over a 3 month period.[4] The MIDAS questionnaire is a simple, self-administered questionnaire consisting of 5 questions. MIDAS has been proved to be highly reliable and correlated with clinical determination regarding the need for medical treatment.[5]

Stellate ganglion, a sympathetic ganglion, innervates the head, neck, and upper extremities. Stellate ganglion block (SGB) improves blood supply to the ipsilateral neck, and upper extremities, which is effective to treat vascular insufficiency.[6,7] In addition, SGB is indicated for the treatment of pain disorders such as herpes zoster and complex regional pain syndrome.[8,9]

In the present study, we found that bilateral SGB is effective to reduce pain and improve MIDAS scores in 2 patients with migraine. Consents for the publication of this report were obtained from all patients.

2. Case presentation
2.1. Case 1
A 48-year-old female presented with a 15-year history of migraine. The headache was bilateral and pulsatile over the frontal and temporal regions, accompanied by nausea and...
Migraine disability assessment (MIDAS) scores reported by patient 1 and 2.

| MIDAS questionnaire                                                                 | Patient 1 Before SGB | Four mo after SGB | Patient 2 Before SGB | Four mo after SGB |
|------------------------------------------------------------------------------------|----------------------|-------------------|----------------------|-------------------|
| On how many days in the last 3 mo did you miss work or school because of your headaches? | 2                    | 0                 | 0                    | 0                 |
| How many days in the last 3 mo was your productivity at work or school reduced by half or more because of your headaches? | 12                   | 3                 | 15                   | 3                 |
| On how many days in the last 3 mo did you not do household work because of your headaches? | 12                   | 0                 | 0                    | 0                 |
| How many days in the last 3 mo your productivity in household work reduced by half or more because of your headaches? | 4                    | 3                 | 15                   | 3                 |
| On how many days in the last 3 mo did you miss family, social, or leisure activities because of your headaches? | 7                    | 0                 | 2                    | 0                 |
| Total score                                                                        | 37                   | 6                 | 32                   | 6                 |
| On how many days in the last 3 mo did you have a headache?                          | 14                   | 3                 | 15                   | 3                 |
| On the scale of 0–10, on average how painful were these headaches? (0 = no pain at all, and 10 = pain as bad as it can be) | 8                    | 4                 | 7                    | 3                 |

Table 1

MIDAS = migraine disability assessment, SGB = stellate ganglion block.

vomiting. The frequency of pain attacks was about 3 times a month and the duration of pain was 48 hours. The pain worsened around the patient’s menstrual cycles. The patient felt fatigue and dizziness 1 day before the onset of headache. The patient was diagnosed with migraine by a neurologist and was taking a daily dose of propranolol 10 mg, naproxen 500 mg, acebutolol 1200 mg, and ergotamine 1 mg. Despite these medications, pain intensity was 6 using visual analog scale (VAS), and MIDAS score was 37 (Table 1). After informed consent was obtained, vital signs were monitored including noninvasive blood pressure, heart rate, and pulse oxygenation, and ultrasonography-guided SGB was performed by injecting 5 mL of 1.5% lidocaine at the anterior aspect of the right 6th cervical spine transverse process. Thirty minutes after the right SGB left SGB was performed with the same volume of lidocaine. No adverse effects such as hypotension, bradycardia, and dyspnea were observed. Bilateral SGB was performed once a week for a month. After the third SGB pain severity was 5 on the VAS and duration of pain was 24 hours. In addition, after the fourth SGB premonitory symptoms such as fatigue and dizziness disappeared and the pain occurred 1 day before menstruation cycle. Therefore, bilateral SGB was performed every month. Four months after bilateral SGB, MIDAS score was 6 and pain was 4 on VAS score, respectively (Table 1) and the patient was treated with oral naproxen 250 mg 2 times a day. However, migraine with pain intensity 4 on VAS continues to occur before 1 day before menstruation cycle. Therefore, patient is still treated with bilateral SGB and oral naproxen 500 mg once a month.

2.2. Case 2

A 43-year-old female presented with a 10-year history of a migraine. She suffered from throbbing and pulsating headaches at bilateral temporal area, accompanied by nausea and vomiting. The headache occurred 2 to 3 times in a month and the duration of pain was 48 to 72 hours. The patient felt neck stiffness, fatigue, and depression 2 days before the onset of headache. She was managed with a combination of drugs, including acetaminophen 325 mg, dichloralphenazone 100 mg, and isometheptene 65 mg 3 times a day, as well as dexibuprofen 300 mg 3 times a day and metoclopramide 10 mg 3 times a day prescribed by a neurologist. Despite these medications, pain intensity was 7 using VAS, while the MIDAS score was 32 (Table 1). After informed consent was obtained, ultrasonography-guided SGB was performed by injecting 5 mL of 1.5% lidocaine at the anterior aspect of the right 6th cervical spine transverse process. Thirty minutes after the right SGB, the left SGB was performed. During the intervention, the patient was monitored with noninvasive blood pressure, heart rate, and pulse oxygenation, and no complications associated with SGB were observed. The patient received bilateral SGB every 2 weeks for a month. After the second bilateral SGB, the incidence and severity of migraine significantly decreased. Pain severity was 4 on the VAS score, which lasted 24 hours. In addition, premonitory symptoms such as fatigue and mood change disappeared and the pain occurred 1 day before menstruation cycle. Therefore, bilateral SGB was performed once a month. Four months after bilateral SGB, the MIDAS score was 6 and pain was 3 on VAS, respectively (Table 1). The pain was treated with oral acetaminophen 600 mg 3 times a day. However, migraine with pain intensity 3 on VAS continues to occur 1 day before menstruation cycle. Therefore, patient is still receiving bilateral SGB and oral acetaminophen 1200 mg once a month.

3. Discussion

Migraine is a common primary headache with a high disability and complex, hereditary neurovascular conditions arising based on functional and structural abnormality of the brain. Migraine predominantly affects females. Although the exact mechanism of migraine remains unclear, it has been suggested that abnormal activation and sensitization of trigeminovascular system play an important role in migraine pathology. Several kinds of neuropeptides, such as calcitonin gene-related peptide,
nitric oxide, serotonin, and glutamate, involved in the pathogenesis of migraine.

The diagnostic criteria for migraine without aura of the third edition of the international classification of headache disorders-3 includes 5 times of migraine attack with following conditions; unilateral, pulsating, moderate or severe pain, pain aggravation by or causing avoidance of routine physical activity. In addition, headache last 4 to 72 hours, accompanied with nausea and/or vomiting, or photophobia and phonophobia. The headache of patient 1 and 2 is compatible with diagnostic criteria for migraine without aura defined by the international classification of headache disorders-3. Some patients with migraine suffer from premonitory symptoms several hours to days before the onset of the headache. The premonitory symptoms are defined as the presence of nonpainful symptomatology, including fatigue, mood change, food craving, and increased yawning and neck stiffness, which may be hypothalamically modulated.

Migraine can severely impact patient’s quality of life. The MIDAS questionnaire assesses headache-related disability over 3 month period. This is regarded as a useful tool to improve communication between physicians and patients and to identify headache patients with significant treatment needs. The MIDAS score is based on 5 disability questions in 3 domains of activity (namely, office, housework, and leisure). It is considered that the patients with MIDAS score 6 or higher need medical care. Many drugs, including beta blockers, antidepressants, nonsteroidal anti-inflammatory drug, ergotamine, and triptan have been used for prevention or management of migraine. However, these medications cannot often alleviate migraine.

In the present case, despite of medications, the MIDAS scores of patient 1 and 2 were 30 and 37, respectively. The stellate ganglion, a sympathetic ganglion innervating the head, neck, and upper extremities, extensively connects with the cerebral cortex, hypothalamus, amygdala, and hippocampus. SGB produces several actions. First, it increases blood supply by sympatholytic effect in its sphere of innervation. Second, SGB inhibits neuronal connections between the stellate ganglion and the brain, which may produce therapeutic effects in various diseases, such as post-herpetic neuralgia, post-traumatic stress disorder, hot flashes and sleep disturbances in breast cancer survivors. In addition, SGB is reported to be effective for treatment of tension headache and headache following post-traumatic stress disorder. The exact mechanism of analgesic action of SGB in these disorders remains unclear. SGB decreases electroencephalogram indices of arousal in animal study and has sedative effects in healthy volunteers. This mechanism of SGB includes restoration of the normal melatonin rhythm. It was reported that patient with migraine have low level of melatonin. Melatonin is effective to prevent migraine by preventing nitric oxide synthesis, inhibiting calcitonin gene-related peptide release, and antagonizing glutamate-induced excitotoxicity. In addition, stress is often cited as a trigger for migraine. In response to stress, sympathetic nerve activity increases, leading to a release of several neurotransmitters associated with pathogenesis of migraine such as dopamine, and prostaglandin. For instance, the excessive dopamine level leads to nausea, vomiting and yawning and the increase of prostaglandin augments pain sensitivity and inflammation in migraine patients. In the present cases 4 months after SGB, patient 1 reported pain intensity of 4 on VAS and 6 on MIDAS and patient 2 rated pain intensity of 3 on VAS, and 6 on MIDAS, respectively. Therefore, we presumed that SGB is effective to improve migraine by restoring normal level of melatonin and decreasing sympathetic activation with response to stress in patient with migraine.

SGB can decrease hemodynamics. Ultrasound-guided peripheral nerve block improves the efficacy of the intervention by direct visualization of the best site for the injection and helps avoid the damage to blood vessels and nerves. In addition, the volume of the injectate can be reduced. In the present study, the left SGB was performed 30 minutes after the right SGB with lidocaine 5 mL under ultrasound-guidance and there were no side effects such as bradycardia and hypotension.

In conclusion, SGB can be an effective option to improve MIDAS scores and pain intensity in patients with refractory migraine. Further prospective controlled studies are needed to define the therapeutic role of SGB in managing migraine patients.

Author contributions
Data collection: Joonhee Lee.
Review and editing: Younghoon Jeon.
Writing – original draft: Suyoung Moon.

References
[1] Annu R, Daniela P, Michael A, et al. Pathophysiology of migraine. Physiology 2013;75:363–91.
[2] Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995;35:387–96.
[3] Lipton RB, Pearlman SH. Transcranial magnetic stimulation in the treatment of migraine. Neurotherapeutics 2010;7:204–12.
[4] Dallof C. Assessment of health-related quality of life in migraine. Cephalalgia 1993;13:123–7.
[5] Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000;88:41–52.
[6] Do S, Cho N, Obara T. Stellate ganglion block increases blood flow in the anastomotic artery after superficial temporal artery-middle cerebral artery bypass. Br J Anaesth 2016;117:395–6.
[7] Yu HG, Chung H, Yoon TG, et al. Stellate ganglion block increases blood flow into the optic nerve head and the peripapillary retina in human. Auton Neurosci 2003;109:53–7.
[8] Kim HJ, Ahn HS, Lee JY, et al. Effects of applying nerve blocks to prevent postherpetic neuralgia in patients with acute herpes zoster: a systematic review and meta-analysis. Korean J Pain 2017;30:3–17.
[9] Datta R, Agrawal J, Sharma A, et al. A study of the efficacy of stellate ganglion blocks in complex regional pain syndromes of the upper body. J Anaesthesiol Clin Pharmacol 2017;33:534–40.
[10] Medrea I, Christi S. Chronic migraine—evolution of the concept and clinical implications. Headache 2018;58:1495–500.
[11] Martins LB, Teixeira AL, Domingues GA. Neurotoxins and migraine. Vitam Horm 2017;104:459–73.
[12] Lukacs M, Tajti J, Fulop F, et al. Migraine, neurogenic inflammation, drug development - pharmacochemical aspects. Curr Med Chem 2017;24:3649–65.
[13] Hoffmann J, Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics 2018;15:361–70.
[14] Olesen J. Headache Classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition, revised. Cephalalgia 2018;38:211–121.
[15] Westerhaus MJ, Loewy AD. Central representation of the sympathetic nervous system in the central cortex. Brain Res 2001;903:117–27.
[16] Hanling SR, Hickey A, Lesnik I, et al. Stellate ganglion block for the treatment of posttraumatic stress disorder: a randomized, double-blind, controlled trial. Reg Anesth Pain Med 2016;41:494–500.
[17] Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008;9:523–32.
[18] Ueshima H. A successful case of stellate ganglion block for difficult therapy of refractory tension headache. J Clin Anesth 2019;54:1.
[19] Chan CW, Chalkiadis GA. A case of sympathetically mediated headache treated with stellate ganglion blockade. Pain Med 2010;11:1294–8.

[20] Jeong S, Jeon Y, Yeo J, et al. The effects of stellate ganglion block on the electroencephalogram in rats. J Anesth 2014;28:601–5.

[21] Yeo J, Jeon Y. Effects of stellate ganglion block on sedation as assessed by bispectral index in normal healthy volunteers. Pain Physician 2015;18:173–8.

[22] Uchida K, Tateda T, Hino H. Novel mechanism of action hypothesized for stellate ganglion block related to melatonin. Med Hypotheses 2002;59:446–9.

[23] Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: a systematic review. Medicine (Baltimore) 2019;98:e14099.

[24] Miano S, Parisi P, Pelliccia A, et al. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 2008;29:283–7.

[25] Todorov LD, Mihaylova-Todorova ST, Bjur RA, et al. Differential cotransmission in sympathetic nerves: role of frequency of stimulation and prejunctional autoreceptors. J Pharmacol Exp Ther 1991;259:241–6.

[26] Sherbourne CD, Gonzales R, Goldyne ME, et al. Norepinephrine-induced increase in sympathetic neuron-derived prostaglandins is independent of neuronal release mechanisms. Neurosci Lett 1992;139:188–90.

[27] Yokoyama K, Sugiyama K. Hemodynamic effects of stellate ganglion block: analysis using a model of aortic input impedance. Can J Anesth 2002;49:887–8.

[28] Jeon YH. Easier and safer regional anesthesia and peripheral nerve block under ultrasound guidance. Korean J Pain 2016;29:1–2.

[29] Narouze S. Ultrasound-guided stellate ganglion block: Safety and efficacy. Curr Pain Headache Rep 2014;18:424–8.